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Abstract
Older patients with newly diagnosed acute myeloid leukemia (AML) in the phase 3 AZA-AML-001 study were evaluated at
entry for cytogenetic abnormalities, and a subgroup of patients was assessed for gene mutations. Patients received azacitidine
75 mg/m2/day x7 days (n= 240) or conventional care regimens (CCR; n= 245): intensive chemotherapy, low-dose
cytarabine, or best supportive care only. Overall survival (OS) was assessed for patients with common (occurring in ≥10% of
patients) cytogenetic abnormalities and karyotypes, and for patients with recurring gene mutations. There was a significant
OS improvement with azacitidine vs CCR for patients with European LeukemiaNet-defined Adverse karyotype (HR 0.71
[95%CI 0.51–0.99]; P= 0.046). Azacitidine-treated patients with -5/5q-, -7/7q-, or 17p abnormalities, or with monosomal or
complex karyotypes, had a 31–46% reduced risk of death vs CCR. The most frequent gene mutations were DNMT3A (27%),
TET2 (25%), IDH2 (23% [R140, 15%; R172, 8%]), and TP53 (21%). Compared with wild-type, OS was significantly
reduced among CCR-treated patients with TP53 or NRAS mutations and azacitidine-treated patients with FLT3 or TET2
mutations. Azacitidine may be a preferred treatment for older patients with AML with Adverse-risk cytogenetics,
particularly those with chromosome 5, 7, and/or 17 abnormalities and complex or monosomal karyotypes. The influence of
gene mutations in azacitidine-treated patients warrants further study.
Introduction
Acute myeloid leukemia (AML) is associated with a range
of recurring cytogenetic abnormalities and gene mutations
[1–4]. While the prognostic importance of cytogenetics in
AML has been established for decades [5], due to
recent advances in next-generation sequencing and greater
availability of myeloid-focused gene panels, some genes
frequently mutated in AML have been identified that are
predictive of treatment response [2, 3, 6]. Molecular genetic
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data are increasingly being used to inform disease classifi-
cation, risk stratification, and clinical care of patients [4, 7].
Two provisional entities, AML with mutated RUNX1 and
AML with BCR-ABL1, have been included in the 2016
update of the World Health Organization (WHO) classifi-
cation of myeloid neoplasms and acute leukemia [7].
Mutational testing for NPM1, CEBPA, and FLT3 is advised
in the 2010 European LeukemiaNet (ELN) recommenda-
tions for AML [1], and the 2017 update to the ELN
recommendations lists three additional genes—RUNX1,
ASXL1, and TP53—that can inform risk stratification,
mainly based on experience with intensive chemother-
apy (IC) in relatively younger patients [4]. Patterns of co-
mutations have also been identified that have distinct prog-
nostic implications in AML [3].
In the randomized, phase 3 AZA-AML-001 study of
older patients with newly diagnosed AML (NCT01074047),
azacitidine prolonged median overall survival (OS) vs
conventional care regimens (CCR) (10.4 vs 6.5 months,
respectively; P= 0.101), with 1-year survival rates of
46.5% vs 34.2%, respectively [8]. A prospective sub-
analysis from the study showed a significantly prolonged
OS of 3.2 months with azacitidine compared with CCR
(hazard ratio [HR] 0.68, 95% confidence interval [95%CI]
0.50, 0.94) in the subgroup of patients with poor-risk
cytogenetics, as defined by National Comprehensive Cancer
Network (NCCN) 2009 criteria [8, 9]. That analysis did not
investigate outcomes associated with specific cytogenetic
abnormalities.
Here we evaluate survival outcomes in patient subgroups
from the AZA-AML-001 study, defined by 2010 ELN
cytogenetic risk classification and by the presence of spe-
cific cytogenetic abnormalities or gene mutations at base-
line. Pretreatment cytogenetic risk classification was an
entry criterion and cytogenetic data were available for
almost all patients. A subpopulation of patients in the AZA-
AML-001 study with available baseline bone marrow
samples for molecular analyses consented to participate in
exploratory analyses, to evaluate the frequency of recurring
gene mutations at entry and relationships between pre-
treatment mutational status and OS.
Methods
Study design
Full study design, patient eligibility criteria, and response
endpoints are described in detail elsewhere [8]. Briefly,
patients aged ≥65 years with newly diagnosed AML, >30%
bone marrow blasts, Eastern Cooperative Oncology Group
performance status (ECOG PS) scores ≤2, white blood cell
counts ≤15 × 109/L, and intermediate- or poor-risk
cytogenetics per 2009 NCCN guidelines for AML [9], were
eligible to participate. This study was approved by all
relevant institutional review boards or independent ethics
committees and was conducted according to the Declaration
of Helsinki. All patients provided written informed consent.
Patients were preselected to 1 of 3 CCR: IC (cytarabine
100–200 mg/m2 IV for 7 days+ anthracycline IV for 3 days
induction), low-dose cytarabine (LDAC; 20 mg SC BID for
10 days per 28-day cycle), or best supportive care (BSC)
only. After preselection, patients were randomized 1:1 to
azacitidine (75 mg/m2/day SC for 7 consecutive days per
28-day cycle) or to CCR; those randomized to CCR
received their preselected regimen. All patients could
receive BSC as needed.
Cytogenetic analyses
Karyotypes from pretreatment bone marrow samples were
determined locally and karyograms were prepared and sent
for central review by an independent cytogeneticist (Anne
Hagemeijer, MD). For these analyses, cytogenetic risk sta-
tus was determined according to modified 2010 ELN
recommendations [1], but molecular markers were not
considered for risk-group assessments, as they were not
available for all patients. Patient subgroups were identified
based on ELN-defined cytogenetic risk classifications:
Intermediate-I (normal karyotype), Intermediate-II (com-
prising all abnormalities not classified as Favorable or
Adverse), and Adverse (Fig 1). OS outcomes associated
with specific cytogenetic abnormalities observed in ≥10% of
patients, and with complex or monosomal karyotypes, were
also evaluated. Complex karyotype was defined as three or
more cytogenetic abnormalities in the absence of a WHO-
designated recurring translocation or inversion; i.e., t(8;21)
(q22;q22.1); t(9;11)(p21.3;q23.3); inv(3)(q21.3q26.2) or
t(3;3)(q21.3;q26.2); t(6;9)(p23;q34.1); t(v;11;q23.3).
Monosomal karyotype was defined as the presence of a
single monosomy (excluding loss of one X or Y chromo-
some) in association with one or more additional monos-
omy or structural chromosomal abnormality. Patients with
multiple lesions may have been assigned to and evaluated in
more than one category. Because the majority (64%) of all
patients in AZA-AML-001 were preselected to receive
LDAC before randomization, OS was also compared among
LDAC-preselected patients who received azacitidine vs
those who received LDAC. The small number of patients
preselected to BSC or IC precluded statistical comparisons
between cytogenetic abnormality subgroups.
Mutational analyses
DNA was isolated from pretreatment bone marrow mono-
nuclear cells and targeted sequencing of 39 genes was
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performed with Haloplex target enrichment (Agilent) on
Illumina HiSeq 2500 using 2 × 100 bp read lengths.
Burrows-Wheeler Aligner (BWA)-MEM alignment to
genome (hg19) and VarScan v2.3.9 software (Genome
Institute at Washington University), a platform-independent
tool, were used to detect variants. Target regions varied by
gene from all exons to hotspots. Variant annotation filtering
included functionally deleterious variants (SnpEff v4.0)
functional prediction as non-synonymous SNV/INDEL in
exons, splicing regions, and stop sites. Pindel (v0.2.5b5)
was used to detect deletions, inversions, small insertions,
and tandem duplicates with the parameter setting at a
minimum coverage of 10 with a minimum of 5 supporting
reads. Heterozygous variant allele frequency (VAF) detec-
tion threshold was 3%. There was a total of 312 variants in
the combined Pindel and VarScan results. FLT3 tyrosine
kinase domain (TKD) mutations were determined by next-
generation sequencing, and internal tandem duplications
(ITD) were determined by capillary electrophoresis sizing
of polymerase chain reaction (PCR) amplicons from exons
14 and 15 (binary call; no allelic ratio data were available).
Statistical methods
Median OS and 1-year survival rates are estimated using
Kaplan–Meier methods. OS comparisons according to 2010
ELN cytogenetic risk status, specific cytogenetic abnorm-
alities, and karyotype are made using a weighted log-rank
test. HRs and 95%CIs are from an unstratified Cox pro-
portional hazards model; P values are from weighted log-
rank tests (not adjusted for multiplicity of testing).
Within each treatment arm (azacitidine or CCR), OS was
compared between patients with specific gene mutations vs
those with corresponding wild-type genes. Additionally, OS
comparisons were made between the azacitidine and CCR
arms for patients with gene mutations detected in ≥5
patients. OS comparisons by gene mutational status are
made using a log-rank test stratified by baseline ECOG PS
score (0–1 vs 2) and NCCN cytogenetic risk (intermediate
vs poor).
The influence of VAFs of gene mutations found to sig-
nificantly influence OS in univariate analyses was investi-
gated in two Cox proportional hazards models [10].
Fig. 1 Patient subgroups according to modified 2010 ELN criteria* and frequency of specific chromosomal abnormalities or karyotypes
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Relative hazards were simulated for VAF from the Cox
proportional hazards models and plotted against the VAF to
visualize the effect of VAF on OS. One model evaluated
relative OS hazards by mutant VAF as a continuous vari-
able vs OS in patients with wild-type corresponding genes
(VAF= 0), with treatment (azacitidine, CCR) as strata in
the model. The second model investigated the relative OS
hazards by baseline mutation VAFs vs wild-type genes
within the azacitidine and CCR arms. When multiple loci
were mutated within a gene, the mutation with the highest
VAF was used in the model.
Results
Patients
The intention-to-treat population in AZA-AML-001 inclu-
ded 488 patients (azacitidine, n= 241; CCR, n= 247) [8].
Of them, centrally reviewed cytogenetic data were available
for 485 patients (99.4%; azacitidine, n= 240; CCR, n=
245, including IC [n= 44], LDAC [n= 158], and BSC only
[n= 45]). In all, 220 patients (45.4%) had ELN-defined
Intermediate-I risk (i.e., normal) karyotype (azacitidine,
n= 114; CCR, n= 106), 111 patients (22.9%) had an
Intermediate-II risk karyotype (azacitidine, n= 53; CCR,
n= 58), and 154 patients (31.8%) had an Adverse risk
karyotype (azacitidine, n= 73; CCR, n= 81) (Fig. 1).
Baseline characteristics of the cytogenetic analysis popula-
tion were essentially unchanged from those of all patients in
the AZA-AML-001 study [8].
The “biomarker cohort” comprised 156 patients who
were assessed at study entry for presence of gene muta-
tions (azacitidine, n= 83; CCR, n= 73). Baseline char-
acteristics were generally similar between azacitidine-
treated and CCR-treated patients (Supplementary Table 1).
Prior history of myelodysplastic syndromes (MDS) was
somewhat more common in azacitidine-treated patients
(23% vs 14% of CCR patients) and CCR-treated patients
were proportionally more likely to have ELN-defined
Adverse risk cytogenetics (44% vs 33%).
Cytogenetic analyses
Median OS was comparable between azacitidine and CCR
among patients with Intermediate-I risk (14.1 vs
10.1 months, respectively; HR 0.83 [95%CI 0.60, 1.1]; P=
0.44) or Intermediate-II risk (8.9 vs 9.6 months; HR 1.19
[95%CI 0.79, 1.8]; P= 0.78) cytogenetics (Fig. 2). Esti-
mated 1-year survival rates in the Intermediate-I risk group
were 60.1% with azacitidine and 45.5% with CCR, and in
the Intermediate-II group were 41.5% and 42.1%, respec-
tively. There was a significant difference in median OS in
favor of azacitidine among patients with Adverse risk kar-
yotypes (5.3 vs 2.9 months with CCR; HR 0.71 [95%CI
0.51, 0.99]; P= 0.046), with estimated 1-year survival rates
of 29.1% vs 14.7% for patients treated with azacitidine and
CCR, respectively.
The LDAC preselection group included 154 patients
treated with azacitidine and 158 patients treated with
LDAC. Median OS with azacitidine and LDAC was 13.3 vs
12.5 months, respectively (HR 1.1 [95%CI 0.75, 1.6]),
among patients with Intermediate-I risk cytogenetics, 10.7
vs 5.6 months (0.93 [0.56, 1.5]) among patients with
Intermediate-II risk cytogenetics, and 5.9 vs 4.3 months
(0.73 [0.47, 1.1]) for those with Adverse risk karyotypes.
Among all patients, those with complex karyotypes (n=
113; 23%), those treated with azacitidine had a statistically
significant improvement in OS compared with those who
received CCR (median 4.8 months vs 2.8 months, respec-
tively; HR 0.64 [95%CI 0.43, 0.94]; P= 0.037) (Fig. 3),
with an estimated 15% more azacitidine-treated patients
alive at 1 year (22.8% vs 7.9%). There was also a trend for
improvement in median OS with azacitidine for patients
with monosomal karyotypes (n= 101, 21%) (5.0 vs
2.8 months with CCR; HR 0.65 [95%CI 0.42, 1.01]; P=
0.055), with estimated 1-year survival rates of 19.6% vs
7.8%, respectively. Within the LDAC preselection group,
median OS among patients with complex karyotypes was
5.3 months with azacitidine vs 2.9 months with LDAC (HR
0.61 [95%CI 0.36, 1.0]), and for patients with monosomal
karyotypes was 5.9 months vs 2.9 months, respectively
(HR 0.66 [0.37, 1.2]).
Specific cytogenetic abnormalities observed in ≥10% of
patients occurred in chromosomes 5 (19%), 7 (15%), and
17p (10%) (Fig. 1). Compared with CCR, treatment
with azacitidine was associated with significantly longer
median OS for patients with complex karyotypes or -7/7q-
abnormalities, and showed a trend for improved survival in
patients with monosomal karyotypes or abnormalities
in chromosomes 5 and 17 (Fig. 3). Median OS in the CCR
arm was less than 3 months for patients in each of these
subgroups.
Mutational analyses
Molecular abnormalities were detected in 33 of the
39 sequenced genes (Fig. 4) and in 153 (98.1%) of the 156
patients in the biomarker population. The most frequently
mutated genes were DNMT3A (27%), TET2 (25%), IDH2
(23% [-R140, 15%; -R172, 8%]), TP53 (21%), RUNX1
(18%), NPM1 (16%), NRAS (12%), FLT3 (12% [-ITD,
10%; -TKD, 5%]), ASXL1 (11%), and STAG2 (10%). No
mutations were found in BRAF, DNMT1, DNMT3B,
FAM5C, HNRNPK, or PTEN genes. No patient with a TP53
mutation had a co-occurring NPM1 or RUNX1 mutation
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(P= 0.002 and P= 0.001, respectively), and 50% of
patients with an FLT3 mutation also had an NPM1 mutation
(P < 0.001) (Supplementary Figure 1). No patient with an
NPM1 mutation had a co-occurring RUNX1 or ASXL1
mutation (P= 0.004 and P= 0.043, respectively). Only 3
patients had a CEBPA mutation and all were monoallelic.
Median OS did not differ significantly in the azacitidine
and CCR arms among patients with 1, 2, or ≥3 gene
mutations at study entry. Within treatment arms, four gene
mutations were significantly correlated with OS compared
with wild-type genes: TP53, NRAS, FLT3 (including both
-ITD and -TKD), and TET2 (Table 1). In the CCR arm,
median OS was significantly reduced for patients with TP53
mutations (n= 17) compared with wild-type (n= 56) (2.4
vs 12.5 months, respectively; P= 0.026) and for patients
with mutant NRAS (n= 8) vs wild-type NRAS (n= 65) (4.3
vs 10.3 months, respectively; P= 0.020) (Fig. 5). Within
the azacitidine arm, median OS was not significantly dif-
ferent between patients with (n= 15) or without (n= 68)
TP53 mutations (7.2 vs 12.0 months, respectively; P=
0.40) or between patients with mutant (n= 10) or wild-type
(n= 73) NRAS (11.8 vs 8.9 months; P= 0.95). However,
median OS in the azacitidine arm was reduced in patients
with mutant FLT3 (n= 9) vs wild-type FLT3 (n= 74) (5.4
vs 12.0 months, respectively; P= 0.017). Despite similar
median OS, there was a statistically significant difference
(P= 0.005) in OS within the azacitidine arm for patients
with TET2 mutations (n= 22) vs those with wild-type TET2
Fig. 2 Overall survival associated with cytogenetic risk groups (per modified 2010 ELN criteria)
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(n= 61) due to separation of the survival curves after the
median (Fig. 5). Median OS within the azacitidine and CCR
treatment arms was comparable for patients with or without
mutations in any of the genes known to influence DNA
methylation (i.e., DNMT3A, IDH1, IDH2, TET1, and
TET2). There were no statistically significant survi-
val differences within either treatment arm for patients with
known or provisional class-defining lesions (e.g., RUNX1,
NPM1) (Table 1), or any other gene mutation evaluated
compared with OS in patients with corresponding wild-type
genes (Supplementary Figure 2).
Survival comparisons between the azacitidine and
CCR arms indicated that patients with mutant TP53 or
NRAS treated with azacitidine had nominally better median
Fig. 3 Overall survival associated with monosomal and complex karyotypes and with specific cytogenetic abnormalities occurring in ≥10% of
patients
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OS than their counterparts in the CCR arm: median OS was
7.2 vs 2.4 months, respectively, for patients with mutant
TP53, and 11.8 vs 4.3 months for those with mutant NRAS
(Table 2). Conversely, azacitidine-treated patients with
TET2 mutations had worse OS outcomes than CCR-treated
patients with the mutation (median OS 9.6 vs 11.1 months,
respectively; P= 0.036). Median OS was similar between
treatment groups for patients with a mutation in any of the
DNA methylation genes.
The influence of VAFs of mutant TP53, NRAS, FLT3-
TKD, and TET2 at baseline on OS vs. wild-type genes in the
Cox model stratified by treatment showed a significant
increase in relative hazards on OS with increasing mutant
TP53 (P < 0.0001) and TET2 (P= 0.042) VAFs
Fig. 4 a Proportions of patients with specific gene mutations. b Oncoplot showing gene mutations in individual patients with intermediate-I/II risk
(green) or poor-risk (orange) cytogenetics
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(Supplementary Figure 3). In individual treatment arms, the
influence of increased TP53 VAF on OS vs wild-type was
both negative and significant in the azacitidine and CCR
arms but was much stronger in the CCR arm (P < 0.0001 vs
P= 0.058 in the CCR vs azacitidine arms, respec-
tively) with higher relative hazard on OS in the CCR arm at
comparable VAF levels. There was a significant correlation
between increased mutant TET2 VAF and OS hazard in the
azacitidine arm (P= 0.0091) but no VAF influence in the
CCR arm (P= 0.97) (Supplementary Figure 4).
Discussion
Prognosis is dismal for older patients with AML and
Adverse-risk cytogenetics, including those with complex or
monosomal karyotypes. Approximately one-third of patients
in AZA-AML-001 had an Adverse karyotype; median OS
among azacitidine-treated patients was almost double that of
patients treated with CCR. Similarly, azacitidine-treated
patients with monosomal or complex karyotypes had 35 and
36% reduced risks of death, respectively, compared with
similar patients who received CCR.
Deletions of part or all of chromosomes 5, 7, or 17 occur
in 5–10% of all patients with AML, are often associated
with complex and monosomal karyotypes, and carry a poor
prognosis [11–13]. They are more common in older patients
and were the most frequent cytogenetic abnormalities in the
AZA-AML-001 study population, occurring in 10–19% of
patients. These chromosomal defects are frequently asso-
ciated with multilineage dysplasia in bone marrow, poor
response to chemotherapy, and high relapse rate [14]. In the
current analyses, median OS was approximately doubled in
azacitidine-treated patients with chromosome 5, 7, or 17
abnormalities compared with similar patients who received
CCR. Similar to reporting in MDS [15], patients with AML
with chromosome 7 abnormalities fared particularly well
with azacitidine, with a median OS improvement of 4.4 (±
0.3) months compared with CCR. Analogous effects with
azacitidine for treatment of AML and MDS would not be
unexpected, as chromosome 5, 7, and 17 defects are diag-
nostic features of AML with myelodysplasia-related chan-
ges (AML-MRC) [4, 16]. The majority of all patients in
AZA-AML-001 (54%) were identified as having AML-
MRC upon central cytogenetic review [14]. Better out-
comes with azacitidine in patients with these specific
cytogenetic abnormalities in the current analysis are con-
sistent with improved survival reported for all azacitidine-
treated patients with AML-MRC in this study, who showed
a median OS prolonged by 4.0 months compared with CCR
(8.9 vs 4.9 months; HR 0.74 [95%CI 0.57, 0.97]) [14].
The genomic landscape differs between younger and
older patients with AML [2]. Mutational frequencies in the
AZA-AML-001 “biomarker” population were as might be
expected for older patients [17–20]. Mutations in genes
encoding epigenetic modifiers, such as DNMT3A, TET2,
and IDH2, are more common in older patients and are
usually acquired early in the evolution of the disease, often
present in the founding clone. Similarly, mutations that are
acquired later (e.g., NPM1 and FLT3) occurred less fre-
quently than what has been reported for other large AML
patient cohorts that included younger patients [3, 21].
Table 1 Median OS within treatment arms (mutant vs wild type) for the most frequently (≥10% of patients) mutated genes and genes involved in
DNA methylation













TP53 12.0 (7.0, 16.3) 7.2 (3.9, 18.6) 0.404 12.5 (9.6, 17.6) 2.4 (1.5, 7.1) 0.026
NRAS 8.9 (5.8, 14.3) 11.8 (7.7, NR) 0.946 10.3 (6.4, 15.1) 4.3 (2.3, NR) 0.020
FLT3a 12.0 (7.6, 16.3) 5.4 (4.5, NR) 0.017 9.6 (5.1, 14.6) 6.4 (3.8, NR) 0.272
TET2 9.5 (6.9, 18.7) 9.6 (4.5, 13.5) 0.005 7.1 (5.6, 14.2) 11.1 (2.8, NR) 0.445
IDH2 9.2 (7.0, 13.3) 12.6 (4.4, NR) 0.602 6.8 (4.9, 14.1) 12.5 (5.6, NR) 0.466
DNMT3A 8.2 (4.8, 14.3) 12.6 (7.0, 20.8) 0.413 8.6 (5.1, 14.3) 10.3 (3.8, NR) 0.597
RUNX1 8.3 (5.1, 13.3) 13.5 (8.8, NR) 0.718 6.1 (3.8, 11.7) 15.8 (12.5, NR) 0.084
NPM1 10.3 (7.2, 14.3) 7.3 (4.5, NR) 0.260 9.6 (5.1, 14.2) 6.4 (3.8, NR) 0.698
ASXL1 8.9 (6.9, 13.2) 18.7 (4.8, NR) 0.229 7.1 (5.1, 14.1) 14.6 (10.0, NR) 0.498
STAG2 8.8 (5.8, 13.2) 19.5 (11.9, NR) 0.469 8.6 (5.6, 14.2) 11.1 (5.1, NR) 0.395
Any DNA
methylation geneb
8.8 (5.4, 18.7) 11.1 (5.8, 15.3) 0.357 6.7 (4.9, 14.2) 12.5 (4.3, 17.6) 0.299
aFLT3-ITD and FLT3-TKD
bIncludes IDH1, IDH2, DNMT3A, TET1, and TET2
MUT mutant gene(s), NR not reached, OS overall survival, WT wild-type gene(s)
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In this analysis, mutations in four genes were shown to
significantly impact survival within treatment arms: mutant
TP53 and NRAS in the CCR arm, and mutant FLT3 and
TET2 in the azacitidine arm. Within the CCR arm, TP53
and NRAS mutations were associated with significantly
reduced OS compared with patients with wild-type genes.
TP53 mutations, which occur in ~5–8% of all patients with
AML [22, 23], are more frequently observed in older
patients (21% of patients in the current study) and patients
with abnormalities of chromosomes 5, 7, or 17p, are asso-
ciated with complex karyotype, and generally indicate a
poor prognosis in hematologic malignancies regardless of
treatment choice [3, 22, 24–29]. However, in keeping with
the current study, it has been suggested that hypomethy-
lating agents (HMAs) may be more effective than conven-
tional care in patients with these mutations. In a study of
decitabine treatment in patients with AML or MDS, those
with TP53 mutations had a 100% response rate compared
with a 41% response rate in patients with wild-type TP53
[30]. During decitabine treatment, TP53 VAF decreased
rapidly to <5% (though the mutation was never completely
cleared); this was accompanied by bone marrow blast
clearance in many instances. In the current analysis, median
OS was prolonged by almost 5 months in patients with
pretreatment TP53 mutations who received azacitidine
compared with similar patients who received CCR. There
was a significant correlation between higher TP53 VAF at
baseline and decreased survival compared with patients
with wild-type TP53 in both treatment arms, but the relative
hazard was much greater in the CCR arm. The prognostic
effects of NRAS mutations, which occur in ~15% of patients
with AML (12% of patients in this study), typically at
Fig. 5 Kaplan–Meier curves for gene mutations significantly (P < 0.05) associated with overall survival within treatment arms (mutant vs wild-
type)
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hotspot regions at codons 12, 13, and 61, are less clear.
Their clinical implications may depend on the co-mutational
context in which they occur, and patterns of NRAS co-
mutations can vary by hotspots within genes [23, 31, 32].
For example, a recent study showed NPM1 mutations to be
preferentially associated with NRASG12/13 but not with
NRASQ61 and that OS outcomes were more favorable when
NRASG12/13 mutations were accompanied by NPM1 and
DNMT3A mutations [3].
TET2 mutations occur in about 7–25% of patients with
AML (25% in this older patient population) [27, 33].
Although median OS within the azacitidine arm for patients
with TET2 mutations differed by only 0.1 month compared
with those without the mutation, the Kaplan–Meier curve
separated after the estimated median, leading to a statisti-
cally significant difference in OS between the two groups.
Median OS was ~1.5 months longer in CCR-treated patients
with TET2 mutations than in similar azacitidine-treated
patients, which was unexpected based on a pathological
feature associated with TET2 mutations (hypermethylation
of DNA) and the purported activity of azacitidine (DNA
demethylation) [34–36]. However, as there were a relatively
small number of azacitidine-treated patients with TET2
mutations in this analysis (n= 22) this finding requires
further confirmation in a larger patient population. When
taken as a group, mutations in genes that regulate DNA
methylation did not influence median OS with azacitidine or
CCR treatment. The prognostic consequences of mutations
in FLT3 may vary based on co-occurring mutations; for
example, when present with an NPM1 mutation in younger
patients, prognosis is somewhat better than if accompanied
by wild-type NPM1 [37]. Approximately 20% of AML
patients present with FLT3 mutations although they are
more common in younger patients with normal karyotype
(only 12% of patients in the current study had an FLT3
mutation) [23, 38]. There was no statistical difference
between azacitidine and CCR treatment in median OS of
patients with FLT3 mutations, but within the azacitidine
arm, presence of a FLT3 mutation at baseline was asso-
ciated with poorer OS compared with wild-type FLT3.
Class-defining NPM1 and a provisional entity, RUNX1 [4],
were among the most commonly mutated genes in the bio-
marker cohort. Although differences in survival were not
statistically significant within treatment arms compared with
the wild-type genes, mutations in NPM1 appeared to confer
somewhat poorer survival, in contrast to what has been shown
in other AML cohorts [39, 40], in both the azacitidine and
CCR treatment arms. Moreover, mutations in RUNX1 were
associated with slightly better median OS in this analysis,
although they have been associated with poorer prognosis in
other studies [41, 42]. The number of patients in this analysis
with mutant NPM1 (n= 25) or RUNX1 (n= 28) were rela-
tively small, and these outcomes highlight a potential limita-
tion of the data; namely, effects of isolated mutations or
chromosomal defects provide only limited information by not
considering cooperating pathogenic mechanisms at work in
any given patient. Another limitation of this analysis is that
changes in molecular and cytogenetic abnormalities during
treatment were not captured.
The extraordinary heterogeneity and complexity of
pathogenic mechanisms found in AML and the interplay
among them in individual patients have made finding a
cure–or even effective treatment–challenging. Nevertheless,
increasing understanding of the genomic basis of AML and
the introduction of new targeted therapies may allow the use
of rational combination treatment regimens that include
broadly effective agents such as azacitidine and an agent
targeting a specific pathogenic pathway to improve patient
outcomes. Studies in AML of azacitidine in combination
with the BCL2 inhibitor, venetoclax (ClinicalTrials.gov
NCT03466294), the mutant IDH inhibitors, enasidenib
and ivosidenib (NCT02677922), and the mutant FLT3
inhibitors, gilteritinib (NCT02752035) and quizartinib
(NCT01892371), are currently ongoing.
The data presented here suggest that azacitidine may be
the preferred treatment for older patients with newly diag-
nosed AML with Adverse-risk cytogenetics who are not
candidates for intensive chemotherapy, particularly those
with chromosome 5, 7, and/or 17 abnormalities, and with
Table 2 Median OS between treatment arms (azacitidine vs CCR) for
the most frequently mutated genes and genes involved in DNA
methylation







TP53 7.2 (3.9, 18.6) 2.4 (1.5, 7.1) 0.093
NRAS 11.8 (7.7, NR) 4.3 (2.3, NR) 0.151
FLT3a 5.4 (4.5, NR) 6.4 (3.8, NR) 0.271
TET2 9.6 (4.5, 13.5) 11.1 (2.8, NR) 0.036
IDH2 12.6 (4.4, NR) 12.5 (5.6, NR) 0.429
DNMT3A 12.6 (7.0, 20.8) 10.3 (3.8, NR) 0.624
RUNX1 13.5 (8.8, NR) 6.4 (3.8, NR) 0.496
NPM1 7.3 (4.5, NR) 12.5 (4.3, 17.6) 0.726
ASXL1 18.7 (4.8, NR) 14.6 (10.0, NR) 0.643
STAG2 19.5 (11.9, NR) 11.1 (5.1, NR) 0.722
Any DNA
methylation geneb
11.1 (5.8, 15.4) 12.5 (4.3,17.6) 0.248
aFLT3-ITD and FLT3-TKD
bIncludes IDH1, IDH2, DNMT3A, TET1, and TET2
NR not reached
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complex or monosomal karyotypes. Moreover, older AML
patients with TP53 or NRAS mutations may have prolonged
survival when treated with azacitidine rather than with
CCR. Outcomes of studies evaluating azacitidine as the
backbone of combination regimens with targeted treatments
are eagerly anticipated.
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